December 19, 2005
Pregnant women living with hepatitis C are about twice as likely to transmit the virus to an infant girl as they are to a boy, according to a study published in the Dec. 1 issue of the Journal of Infectious Diseases, Reuters Health reports. Pier-Angelo Tovo from the Universita degli Studi di Torino in Turin, Italy, and colleagues examined 1,787 pregnant women living with hepatitis C and their infants at 33 centers in Europe and recorded a mother-to-child transmission rate of 6.2%. The researchers also found that elective delivery by caesarean section did not prevent infants from contracting the virus. In addition, breastfeeding, maternal history of injection drug use and premature birth were not significantly associated with higher rates of vertical transmission of hepatitis C, according to the study (Reuters Health, 12/15). Women co-infected with HIV and hepatitis C had a higher hepatitis C transmission rate -- 8.7% -- than the other women participating in the study -- 5.5% -- but the finding was not statistically significant (Tovo et al., Journal of Infectious Diseases, 12/1). The researchers said the higher rate of hepatitis C infection among infant girls suggests hormonal or genetic differences between girls and boys affect an infant's risk of contracting the virus. In an accompanying JID editorial, Palmer Beasley from the University of Texas School of Public Health said that the study's finding on gender differences is "interesting, provocative and worth further investigation." Beasley adds that the finding is consistant with recent observations regarding gender differences in vertical HIV transmission (Reuters Health, 12/15).
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2005 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|What's Hot in HIV Cure Research?|
|Extensively Drug-Resistant HIV Yields to a New Drug: Ibalizumab|
|A Review of Long-Acting HIV Treatment and Prevention|
|Top Menu Items From the Boiling Cauldron of HIV Clinical Research|
|This Week in HIV Research: Researchers Exonerate Long-Alleged 'Patient Zero,' and Triggering bNAb Production Shows Promise|